Research programme: gastric acid pump antagonists - RaQualia PharmaAlternative Names: RQ-00000774
Latest Information Update: 30 Jun 2015
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Gastro-oesophageal reflux